- Home
- ENGN vs ADCT Comparison
ENGN vs ADCT Comparison
Compare ENGN & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENGN
- ADCT
- Stock Information
- Founded
- ENGN 1999
- ADCT 2011
- Country
- ENGN Canada
- ADCT Switzerland
- Employees
- ENGN N/A
- ADCT N/A
- Industry
- ENGN
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- ENGN
- ADCT Health Care
- Exchange
- ENGN Nasdaq
- ADCT Nasdaq
- Market Cap
- ENGN 293.1M
- ADCT 224.3M
- IPO Year
- ENGN N/A
- ADCT 2020
- Fundamental
- Price
- ENGN $8.65
- ADCT $2.10
- Analyst Decision
- ENGN Strong Buy
- ADCT Strong Buy
- Analyst Count
- ENGN 8
- ADCT 5
- Target Price
- ENGN $30.38
- ADCT $7.33
- AVG Volume (30 Days)
- ENGN 136.6K
- ADCT 465.2K
- Earning Date
- ENGN 01-27-2025
- ADCT 11-07-2024
- Dividend Yield
- ENGN N/A
- ADCT N/A
- EPS Growth
- ENGN N/A
- ADCT N/A
- EPS
- ENGN N/A
- ADCT N/A
- Revenue
- ENGN N/A
- ADCT $70,717,000.00
- Revenue This Year
- ENGN N/A
- ADCT $6.38
- Revenue Next Year
- ENGN N/A
- ADCT $11.73
- P/E Ratio
- ENGN N/A
- ADCT N/A
- Revenue Growth
- ENGN N/A
- ADCT N/A
- 52 Week Low
- ENGN $4.42
- ADCT $0.94
- 52 Week High
- ENGN $18.40
- ADCT $6.04
- Technical
- Relative Strength Index (RSI)
- ENGN 56.95
- ADCT 37.08
- Support Level
- ENGN $8.00
- ADCT $2.06
- Resistance Level
- ENGN $9.60
- ADCT $2.38
- Average True Range (ATR)
- ENGN 0.59
- ADCT 0.21
- MACD
- ENGN 0.06
- ADCT 0.00
- Stochastic Oscillator
- ENGN 58.70
- ADCT 23.27
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.